0.66 USD
-0.03 (-4.51%)
0.66 USD
0 (0%)
Overall ICCM gets a fundamental rating of 3 out of 10. We evaluated ICCM against 187 industry peers in the Health Care Equipment & Supplies industry. While ICCM seems to be doing ok healthwise, there are quite some concerns on its profitability. ICCM is quite expensive at the moment. It does show a decent growth rate.
1. Profitability
1.1 Basic Checks
In the past year ICCM has reported negative net income.
ICCM had a negative operating cash flow in the past year.
In the past 5 years ICCM always reported negative net income.
In the past 5 years ICCM always reported negative operating cash flow.
1.2 Ratios
Looking at the Return On Assets, with a value of -101.41%, ICCM is doing worse than 79.68% of the companies in the same industry.
Looking at the Return On Equity, with a value of -164.30%, ICCM is doing worse than 69.52% of the companies in the same industry.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| ROA | -101.41% | ||
| ROE | -164.3% | ||
| ROIC | N/A |
ROA(3y)-89.11%
ROA(5y)-66.89%
ROE(3y)-136.41%
ROE(5y)-102.39%
ROIC(3y)N/A
ROIC(5y)N/A
1.3 Margins
ICCM has a worse Gross Margin (35.06%) than 72.19% of its industry peers.
In the last couple of years the Gross Margin of ICCM has grown nicely.
The Profit Margin and Operating Margin are not available for ICCM so they could not be analyzed.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| OM | N/A | ||
| PM (TTM) | N/A | ||
| GM | 35.06% |
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3Y-6.03%
GM growth 5Y4.86%
2. Health
2.1 Basic Checks
ICCM does not have a ROIC to compare to the WACC, probably because it is not profitable.
ICCM has more shares outstanding than it did 1 year ago.
The number of shares outstanding for ICCM has been increased compared to 5 years ago.
There is no outstanding debt for ICCM. This means it has a Debt/Equity and Debt/FCF ratio of 0 and it is amongst the best of the sector and industry.
2.2 Solvency
ICCM has an Altman-Z score of -8.38. This is a bad value and indicates that ICCM is not financially healthy and even has some risk of bankruptcy.
Looking at the Altman-Z score, with a value of -8.38, ICCM is doing worse than 77.01% of the companies in the same industry.
ICCM has no outstanding debt. Therefor its Debt/Equity and Debt/FCF ratios are 0 and belong to the best of the industry.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Debt/Equity | 0 | ||
| Debt/FCF | N/A | ||
| Altman-Z | -8.38 |
ROIC/WACCN/A
WACC8.61%
2.3 Liquidity
ICCM has a Current Ratio of 2.38. This indicates that ICCM is financially healthy and has no problem in meeting its short term obligations.
Looking at the Current ratio, with a value of 2.38, ICCM is in line with its industry, outperforming 44.92% of the companies in the same industry.
A Quick Ratio of 1.90 indicates that ICCM should not have too much problems paying its short term obligations.
ICCM has a Quick ratio of 1.90. This is comparable to the rest of the industry: ICCM outperforms 50.27% of its industry peers.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Current Ratio | 2.38 | ||
| Quick Ratio | 1.9 |
3. Growth
3.1 Past
ICCM shows a strong growth in Earnings Per Share. In the last year, the EPS has been growing by 8.77%, which is quite good.
Looking at the last year, ICCM shows a very negative growth in Revenue. The Revenue has decreased by -18.96% in the last year.
ICCM shows quite a strong growth in Revenue. Measured over the last years, the Revenue has been growing by 15.37% yearly.
EPS 1Y (TTM)8.77%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%25%
Revenue 1Y (TTM)-18.96%
Revenue growth 3Y-7.36%
Revenue growth 5Y15.37%
Sales Q2Q%28.4%
3.2 Future
Based on estimates for the next years, ICCM will show a very strong growth in Earnings Per Share. The EPS will grow by 23.59% on average per year.
Based on estimates for the next years, ICCM will show a very strong growth in Revenue. The Revenue will grow by 90.27% on average per year.
EPS Next Y26.9%
EPS Next 2Y22.76%
EPS Next 3Y20.78%
EPS Next 5Y23.59%
Revenue Next Year5.29%
Revenue Next 2Y20.78%
Revenue Next 3Y104.63%
Revenue Next 5Y90.27%
3.3 Evolution
When comparing the Revenue growth rate of the last years to the growth rate of the upcoming years, we see that the growth is accelerating.
4. Valuation
4.1 Price/Earnings Ratio
The Price/Earnings Ratio is negative for ICCM. In the last year negative earnings were reported.
Besides the negative Price/Earnings Ratio, also the Forward Price/Earnings Ratio is negative for ICCM. No positive earnings are expected for the next year.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PE | N/A | ||
| Fwd PE | N/A |
4.2 Price Multiples
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| P/FCF | N/A | ||
| EV/EBITDA | N/A |
4.3 Compensation for Growth
A more expensive valuation may be justified as ICCM's earnings are expected to grow with 20.78% in the coming years.
PEG (NY)N/A
PEG (5Y)N/A
EPS Next 2Y22.76%
EPS Next 3Y20.78%
5. Dividend
5.1 Amount
No dividends for ICCM!.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Dividend Yield | N/A |
0.66
-0.03 (-4.51%)
Chartmill FA Rating
GICS SectorHealth Care
GICS IndustryGroupHealth Care Equipment & Services
GICS IndustryHealth Care Equipment & Supplies
Earnings (Last)
Earnings (Next)
Inst Owners0.38%
Inst Owner Change26.19%
Ins Owners40.42%
Ins Owner ChangeN/A
Market Cap45.51M
Revenue(TTM)2.98M
Net Income(TTM)-15.29M
Analysts82.5
Price Target3.19 (383.33%)
Short Float %2.93%
Short Ratio0.99
Dividend
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Dividend Yield | N/A |
Yearly DividendN/A
Dividend Growth(5Y)N/A
DPN/A
Div Incr Years0
Div Non Decr Years0
Ex-DateN/A
Surprises & Revisions
EPS beat(2)1
Avg EPS beat(2)-4.07%
Min EPS beat(2)-17.65%
Max EPS beat(2)9.5%
EPS beat(4)2
Avg EPS beat(4)3.44%
Min EPS beat(4)-17.65%
Max EPS beat(4)26.47%
EPS beat(8)5
Avg EPS beat(8)4.51%
EPS beat(12)8
Avg EPS beat(12)5.2%
EPS beat(16)N/A
Avg EPS beat(16)N/A
Revenue beat(2)1
Avg Revenue beat(2)-2.8%
Min Revenue beat(2)-22.31%
Max Revenue beat(2)16.71%
Revenue beat(4)1
Avg Revenue beat(4)-7.62%
Min Revenue beat(4)-22.31%
Max Revenue beat(4)16.71%
Revenue beat(8)3
Avg Revenue beat(8)-5.39%
Revenue beat(12)3
Avg Revenue beat(12)-12.47%
Revenue beat(16)N/A
Avg Revenue beat(16)N/A
PT rev (1m)7.14%
PT rev (3m)20.66%
EPS NQ rev (1m)3.58%
EPS NQ rev (3m)10%
EPS NY rev (1m)0.77%
EPS NY rev (3m)-4.03%
Revenue NQ rev (1m)17.31%
Revenue NQ rev (3m)74.46%
Revenue NY rev (1m)10.45%
Revenue NY rev (3m)-29.88%
Valuation
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PE | N/A | ||
| Fwd PE | N/A | ||
| P/S | 15.3 | ||
| P/FCF | N/A | ||
| P/OCF | N/A | ||
| P/B | 4.89 | ||
| P/tB | 4.89 | ||
| EV/EBITDA | N/A |
EPS(TTM)-0.26
EYN/A
EPS(NY)-0.15
Fwd EYN/A
FCF(TTM)-0.2
FCFYN/A
OCF(TTM)-0.2
OCFYN/A
SpS0.04
BVpS0.13
TBVpS0.13
PEG (NY)N/A
PEG (5Y)N/A
Graham NumberN/A
Profitability
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| ROA | -101.41% | ||
| ROE | -164.3% | ||
| ROCE | N/A | ||
| ROIC | N/A | ||
| ROICexc | N/A | ||
| ROICexgc | N/A | ||
| OM | N/A | ||
| PM (TTM) | N/A | ||
| GM | 35.06% | ||
| FCFM | N/A |
ROA(3y)-89.11%
ROA(5y)-66.89%
ROE(3y)-136.41%
ROE(5y)-102.39%
ROIC(3y)N/A
ROIC(5y)N/A
ROICexc(3y)N/A
ROICexc(5y)N/A
ROICexgc(3y)N/A
ROICexgc(5y)N/A
ROCE(3y)N/A
ROCE(5y)N/A
ROICexgc growth 3YN/A
ROICexgc growth 5YN/A
ROICexc growth 3YN/A
ROICexc growth 5YN/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3Y-6.03%
GM growth 5Y4.86%
F-Score2
Asset Turnover0.2
Health
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Debt/Equity | 0 | ||
| Debt/FCF | N/A | ||
| Debt/EBITDA | N/A | ||
| Cap/Depr | 11.76% | ||
| Cap/Sales | 1.21% | ||
| Interest Coverage | N/A | ||
| Cash Conversion | N/A | ||
| Profit Quality | N/A | ||
| Current Ratio | 2.38 | ||
| Quick Ratio | 1.9 | ||
| Altman-Z | -8.38 |
F-Score2
WACC8.61%
ROIC/WACCN/A
Cap/Depr(3y)175.33%
Cap/Depr(5y)260.07%
Cap/Sales(3y)15.28%
Cap/Sales(5y)12.86%
Profit Quality(3y)N/A
Profit Quality(5y)N/A
High Growth Momentum
Growth
EPS 1Y (TTM)8.77%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%25%
EPS Next Y26.9%
EPS Next 2Y22.76%
EPS Next 3Y20.78%
EPS Next 5Y23.59%
Revenue 1Y (TTM)-18.96%
Revenue growth 3Y-7.36%
Revenue growth 5Y15.37%
Sales Q2Q%28.4%
Revenue Next Year5.29%
Revenue Next 2Y20.78%
Revenue Next 3Y104.63%
Revenue Next 5Y90.27%
EBIT growth 1Y-5.6%
EBIT growth 3YN/A
EBIT growth 5YN/A
EBIT Next YearN/A
EBIT Next 3YN/A
EBIT Next 5YN/A
FCF growth 1Y4.96%
FCF growth 3YN/A
FCF growth 5YN/A
OCF growth 1Y1.83%
OCF growth 3YN/A
OCF growth 5YN/A
ICECURE MEDICAL LTD / ICCM FAQ
What is the fundamental rating for ICCM stock?
ChartMill assigns a fundamental rating of 3 / 10 to ICCM.
Can you provide the valuation status for ICECURE MEDICAL LTD?
ChartMill assigns a valuation rating of 1 / 10 to ICECURE MEDICAL LTD (ICCM). This can be considered as Overvalued.
Can you provide the profitability details for ICECURE MEDICAL LTD?
ICECURE MEDICAL LTD (ICCM) has a profitability rating of 1 / 10.
How financially healthy is ICECURE MEDICAL LTD?
The financial health rating of ICECURE MEDICAL LTD (ICCM) is 5 / 10.
What is the expected EPS growth for ICECURE MEDICAL LTD (ICCM) stock?
The Earnings per Share (EPS) of ICECURE MEDICAL LTD (ICCM) is expected to grow by 26.9% in the next year.